GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Onesource Specialty Pharma Ltd

Onesource Specialty Pharma: Q4 FY26 Revenue up 47% QoQ to ₹4,282 million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 13 May 2026, 01:41 PM IST  ·  BSE ID: 0b12aac7-daa6-492f-b11e-896e3417b42e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's quarterly revenue and profit increased significantly, driven by new product launches and overall business growth.
🤖 AI Summary
  • OneSource Specialty Pharma reported Q4 FY26 revenues of ₹4,282 million, increasing 47% QoQ.
  • EBITDA for Q4 FY26 reached ₹919 million, marking a 5x+ quarter-on-quarter expansion.
  • Adjusted PAT for Q4 FY26 was ₹390 million, transitioning from a loss in Q3 FY26.
  • The company reaffirmed its FY28 guidance: ~$400 million in organic revenue with ~40% EBITDA margin.
  • Q4 performance was driven by broad business momentum and India semaglutide commercial launches.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q4 FY26 Revenues
₹4,282 million
Q3 FY26 Revenues
₹2,903 million
47%
Q4 FY26 EBITDA
₹919 million
Q3 FY26 EBITDA
₹173 million
5x+
Q4 FY26 Adjusted PAT
₹390 million
Loss to profit
Q4 FY26 Adjusted EPS
₹3.4
Loss to profit
FY26 Revenues
₹14,216 million
-2%
FY25 Revenues
₹14,449 million
FY26 EBITDA
₹3,042 million
-35%
FY25 EBITDA
₹4,665 million
FY26 Adjusted PAT
₹739 million
-68%
FY25 Adjusted PAT
₹2,314 million
FY26 Adjusted EPS
₹6.5
-69%
FY25 Adjusted EPS
₹21.0
🏢 How This Affects the Company
📈
Business Impact
The company reported growth across all service offerings, including new semaglutide launches in India and US injectables/soft-gelatin businesses, suggesting expanded market reach and product portfolio contribution. Approvals in Canada support continued growth momentum.
💰
Financial Impact
Q4 FY26 revenues increased by 47% QoQ to ₹4,282 million, with EBITDA expanding over 5x to ₹919 million. Adjusted PAT moved from a loss to ₹390 million, improving quarterly profitability.
⚙️
Operational Impact
The DDC facility ramp-up in FY26 contributed to an elevated cost base, while successful semaglutide launches in India across multiple customer brands indicate increased commercialisation activities.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with FY26 Adjusted EPS at ₹6.5, down 69% YoY from ₹21.0 in FY25.
🔍
Management Signal
Management signals a commitment to growth momentum into FY27 through continued semaglutide launches and biologics pipeline expansion, while reaffirming long-term FY28 guidance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q1 FY27 results — monitor for sustained QoQ revenue and EBITDA growth.
Updates on semaglutide approvals in Canada and related commercialisation impact.
Filings on progress towards FY28 guidance of ~$400 million organic revenue.
MEDIUM RISK FY26 saw significant YoY declines in EBITDA and Adjusted PAT, coupled with revenue dip.
💡 Investor Takeaway
Onesource Specialty Pharma's Q4 FY26 revenues rose 47% QoQ to ₹4,282 million, with EBITDA expanding over 5x QoQ to ₹919 million and Adjusted PAT reaching ₹390 million. The company reaffirms its FY28 guidance of ~$400 million organic revenue and ~40% EBITDA margin, supported by semaglutide launches.
⚖️ Strengths & Concerns

✅ Positives

  • Q4 FY26 Revenues increased 47% QoQ to ₹4,282 million, demonstrating sequential business recovery.
  • Q4 FY26 EBITDA expanded over 5x QoQ to ₹919 million, reflecting operating leverage on higher CSA revenues.

⚠️ Concerns

  • FY26 Revenues decreased by 2% YoY to ₹14,216 million, impacted by delayed semaglutide approvals in Canada.
  • FY26 EBITDA declined 35% YoY to ₹3,042 million, reflecting a high MSA base in the prior year and elevated costs for DDC facility ramp-up.
📅 Company Track Record
No previous filings or specific historical financial data for Onesource Specialty Pharma Ltd. were available for context, making this the first public financial announcement for the company on ForgeUp.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.